B.y.m. Technologies secures £210k for biotech development

B.y.m. Technologies Ltd creates a natural serum designed to protect and re-establish the microbiome. The business uses its proprietary bacterium, B.Y.M.® 1405, to target the women's intimate health market from its headquarters in London.

A recent funding round has brought in approximately £210.1k for the company. This capital injection was allotted in June 2026, with formal documentation filed during the same month, representing the total investment raised by the entity during the current year.

Incorporated in 2019, the firm focuses on research and experimental development within natural sciences and engineering. Financial records for the year ending 31 May 2025 show a team of three employees.